FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

784411004: Caplacizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3764507011 Caplacizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3764508018 Caplacizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
5592341000241115 caplacizumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Caplacizumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Platelet aggregation inhibitor (disposition) true Inferred relationship Some
Caplacizumab (substance) Is a Platelet aggregation inhibitor true Inferred relationship Some
Caplacizumab (substance) Is a Monoclonal antibody true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Caplacizumab-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Caplacizumab (substance) Inferred relationship Some 1
Product containing only caplacizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Caplacizumab (substance) Inferred relationship Some 1
Caplacizumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Caplacizumab (substance) Inferred relationship Some 1
Caplacizumab only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Caplacizumab (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start